Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
复制标题
用于预释放囚犯的缓释纳曲酮：医疗移动治疗的随机试验。
DOI：
10.1016/j.cct.2016.12.015
复制
发表时间：
2017
影响因子：
2.2
通讯作者：
O'Brien,CharlesP
中科院分区：
文献类型：
--
作者：
Gordon,MichaelS;Vocci,FrankJ;Fitzgerald,TerrenceT;O'Grady,KevinE;O'Brien,CharlesP
缓释纳洛酮（XR-NTX）是阿片类药物使用障碍的有效治疗方法，但很少在美国监狱或刑事司法人群中使用。慢性病的移动的治疗已在各种环境中实施。移动的治疗可以提供一个机会，扩大外展假释，以克服传统的诊所treatment.MethodsMale和女性囚犯（240）的阿片类药物使用障碍的监禁前的历史，谁是在一个月内从监狱释放将被纳入本随机临床试验。参与者被随机分配到两个研究组中的一个：1）[XR-NTX-OTx]在监狱中注射一次长效纳洛酮，然后在社区阿片类药物治疗计划中释放后每月注射6次;或2）[XR-NTX + MMTx]在监狱中注射一次长效纳洛酮，然后在释放后使用移动的医疗在患者的居住地每月注射6次。主要结果是：治疗依从性;使用阿片类药物;犯罪活动;再次逮捕;重新监禁;和艾滋病毒的危险行为。ResultsWe描述的背景和理由的研究，其目的，假设，和研究design.ConclusionsThe使用长效注射纳洛酮可能是一个有前途的形式的治疗预释放囚犯。最后，由于刑事司法系统中有许多人退出治疗，本研究将评估在其居住地接受治疗是否会提高依从性并对治疗产生积极影响outcomes.ClinicalTrials.gov：NCT 02867124
BackgroundExtended-release naltrexone (XR-NTX), is an effective treatment for opioid use disorder but is rarely initiated in US prisons or with criminal justice populations. Mobile treatment for chronic diseases has been implemented in a variety of settings. Mobile treatment may provide an opportunity to expand outreach to parolees to surmount barriers to traditional clinic treatment.MethodsMale and female prisoners (240) with pre-incarceration histories of opioid use disorder who are within one month of release from prison will be enrolled in this randomized clinical trial. Participants are randomized to one of two study arms: 1) [XR-NTX-OTx] One injection of long-acting naltrexone in prison, followed by 6 monthly injections post-release at a community opioid treatment program; or 2) [XR-NTX + MMTx] One injection of long-acting naltrexone in prison followed by 6 monthly injections post-release at the patient's place of residence utilizing mobile medical treatment. The primary outcomes are: treatment adherence; opioid use; criminal activity; re-arrest; reincarceration; and HIV risk-behaviors.ResultsWe describe the background and rationale for the study, its aims, hypotheses, and study design.ConclusionsThe use of long-acting injectable naltrexone may be a promising form of treatment for pre-release prisoners. Finally, as many individuals in the criminal justice system drop out of treatment, this study will assess whether treatment at their place of residence will improve adherence and positively affect treatment outcomes.ClinicalTrials.gov: NCT02867124